Download the PDF here
 
Vir Biotechnology, Inc. - Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
 
- Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 -
 
- Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts -
 
- Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares -
 
- Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 -
 
- New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a